|
Interferon alfa-n3
resources
|
|
|
|
|
|
DRUG INFO
Interferon alfa-n3
Drug Name:
Interferon alfa-n3
Indication: For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.
Mechanism Of Action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Drug Category: Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents
Brand Names/Synonyms: Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; Alferon (Interferon Sciences Inc.)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human interferon alpha (2a, 2b and 2c)
Chemical Formula: C860H1353N227O255S9
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00023
CAS Registry Number: 11/1/9008
|
|
|
|
|
|
Interferon alfa-n3 News
(When available)
Hemispherx to Present at the 4th Annual Biodefense Research ... Dec 20, 2005
Business Wire (press release), Hemispherx will present the results from the experimental trials for Alferon N Low Dose Oral (LDO) that are taking place with internationally recognized ...
Hemispherx Highlighted in Study of Innate Immunity as a Defense ... Dec 13, 2005
Business Wire (press release), Immunology (JACI) (December issue) titled "Innate Immunity for Biodefense: A Strategy whose Time has Come" have found that Hemispherx products Alferon N(R) and ...
Hemispherx Biopharma Letter to Shareholders Jan 3, 2006
Business Wire (press release), DC) we will unveil exciting new results in both the avian flu vaccine augmentation and the potential broad-spectrum antiviral activities of Alferon N(TM) and ...
|
|
|
